Literature DB >> 12937016

Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.

G A Pankuch1, M R Jacobs, P C Appelbaum.   

Abstract

Daptomycin mean staphylococcal postantibiotic effects (PAEs) were 1.1 to 6.2 h, with a mean of 2.5 h. The mean pneumococcal PAEs were 1.7 h, ranging between 1.0 and 2.5 h. The staphylococcal and pneumococcal postantibiotic sub-MIC effects at 0.4 times the MIC ranged from 3.0 to >12.0 h and 1.9 to >12.0 h, respectively.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12937016      PMCID： PMC182610          DOI： 10.1128/AAC.47.9.3012-3014.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Pharmacodynamic effects of subinhibitory antibiotic concentrations.

Authors:  I Odenholt
Journal:  Int J Antimicrob Agents       Date:  2001-01       Impact factor: 5.283

2.  Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers.

Authors:  R Wise; T Gee; J M Andrews; B Dvorchik; G Marshall
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vitro bactericidal activity of daptomycin against staphylococci.

Authors:  Peter C Fuchs; Arthur L Barry; Steven D Brown
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

4.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  L Licata; C E Smith; R M Goldschmidt; J F Barrett; M Frosco
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Authors:  H Hanberger; L E Nilsson; R Maller; B Isaksson
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 9.  Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens.

Authors:  W Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

10.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
View more
  7 in total

1.  Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.

Authors:  Jun Taek Oh; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant.

Authors:  Dominique Dugourd; Haiyan Yang; Melissa Elliott; Raymond Siu; Jacob J Clement; Suzana K Straus; Robert E W Hancock; Evelina Rubinchik
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 3.  Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.

Authors:  Philip I Hair; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Design and pharmacodynamics of recombinant NZ2114 histidine mutants with improved activity against methicillin-resistant Staphylococcus aureus.

Authors:  Huixian Chen; Ruoyu Mao; Da Teng; Xiumin Wang; Ya Hao; Xingjun Feng; Jianhua Wang
Journal:  AMB Express       Date:  2017-02-22       Impact factor: 3.298

5.  Antibacterial and immunomodulatory activities of insect defensins-DLP2 and DLP4 against multidrug-resistant Staphylococcus aureus.

Authors:  Zhanzhan Li; Ruoyu Mao; Da Teng; Ya Hao; Huixian Chen; Xiumin Wang; Xiao Wang; Na Yang; Jianhua Wang
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

Review 6.  Daptomycin: a cyclic lipopeptide antimicrobial agent.

Authors:  LilyAnn Jeu; Horatio B Fung
Journal:  Clin Ther       Date:  2004-11       Impact factor: 3.393

7.  A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.

Authors:  D Matthew Shoemaker; Jikerkhoun Simou; William E Roland
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.